Phenotypic Characterization of HIV-Specific CD8+ T Cells during Early and Chronic Infant HIV-1 Infection by Slyker, Jennifer A. et al.
Phenotypic Characterization of HIV-Specific CD8
+ T Cells
during Early and Chronic Infant HIV-1 Infection
Jennifer A. Slyker
1,2,3*, Grace C. John-Stewart
2,3,4, Tao Dong
1, Barbara Lohman-Payne
2,3,5, Marie Reilly
6,
Ann Atzberger
7, Stephen Taylor
8, Elizabeth Maleche-Obimbo
5, Dorothy Mbori-Ngacha
5, Sarah L.
Rowland-Jones
1
1MRC Human Immunology Unit, Oxford University, Oxford, United Kingdom, 2Department of Global Health, University of Washington, Seattle, Washington, United States
of America, 3Department of Medicine, University of Washington, Seattle, Washington, United States of America, 4Department of Epidemiology, University of Washington,
Seattle, Washington, United States of America, 5Department of Paediatrics, University of Nairobi, Nairobi, Kenya, 6Medical Epidemiology & Biostatistics, Karolinska
Institutet, Stockholm, Sweden, 7Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, Oxford University, Oxford, United Kingdom, 8Computational
Biology Research Group, Weatherall Institute of Molecular Medicine, Oxford University, Oxford, United Kingdom
Abstract
Although CD8
+ T cells play an important role in the containment of adult HIV-1 replication, their role in infant HIV-1
infection is not as well understood. Impaired HIV-specific CD8
+ T cell responses may underlie the persistently high viral loads
observed in infants. We examined the frequency and phenotype of infant HIV-specific CD8
+ T cells in 7 HIV-infected
antiretroviral therapy-naı ¨ve infants during the first 2 years of life, using class I HLA tetramers and IFN-c-ELISPOT. The
frequency (0.088–3.9% of CD3
+CD8
+ cells) and phenotype (CD27
+CD28
2, CD45RA
+/2, CD57
+/2, HLA-DR
+, CD95
+) of infant
HIV-specific CD8
+ T cells were similar to reports in adults undergoing early infection. Unlike adults, at 23–24 months post-
infection a high frequency of HIV-specific CD8
+ T cells expressed HLA-DR (mean 80%, range 68–85%) and CD95 (mean 88%,
range 79–96%), suggesting sustained activation and vulnerability to apoptosis. Despite comparable expansion of HIV-
specific CD8
+ T cells of a similar phenotype to adults during early infection, infant T cells failed to contain HIV-1 replication,
and remained persistently activated and vulnerable to apoptosis during chronic infection.
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Introduction
The natural history of human immunodeficiency virus type-1
(HIV-1) infection in infants differs markedly from adults. In adults,
plasma viral load peaks during acute infection and is subsequently
reduced to a .1 log lower level set-point over the next 6–8 weeks
[1]. This viral load set-point may be maintained for years,
sometimes at levels below detection. In contrast, infants experience
very high plasma viral loads (often more than 1 million copies/ml)
and lack the characteristic decline to set-point observed in adults
[2,3,4,5,6]. Infant CD4
+ T cells are rapidly depleted during the
first year of life and there is much morbidity due to opportunistic
infection. In the absence of antiretroviral therapy (ART), 2-year
mortality rates as high as 52% have been reported in African
cohorts [7,8,9,10].
Adult studies of HIV-1 infection and SIV models have
demonstrated the importance of HIV-specific CD8
+ T cells in
limiting viral replication [11,12,13,14]. The rapid HIV-1 disease
progression experienced by infants may be a consequence of
suboptimal T cell responses during early life. Studies conducted in
perinatally infected infants report less frequent detection of CD8
+
T cell responses, and responses of a smaller magnitude than are
typically observed in HIV-infected adults [15,16]. There are
conflicting findings regarding the association between CD8
+ T cell
responses and HIV-1 viral load or disease progression in infants
and children; with some studies showing a positive, negative, or
absence of correlation [16,17,18,19,20]. The detection of escape
mutations suggests some infant CD8
+ T cells exert sufficient
selection pressure to drive viral evolution [21,22]. In 85 vertically
infected infants examined longitudinally during the first year of
life, we observed an increase in the magnitude of HIV-specific
IFN-c responses over time [17]. We also found infants who
acquired HIV-1 after 1 month of age were able to generate IFN-c
responses more rapidly than infants with in utero or peripartum
infection [23]. Together these data suggest that the capacity of the
infant cellular immune system to generate HIV-specific IFN-c
responses increases rapidly in the first months of life.
Understanding the specific mechanisms by which infant T cells
fail to contain HIV-1 is important to the design of vaccines
appropriate for use in infants. In addition, defects in infant
PLoS ONE | www.plosone.org 1 May 2011 | Volume 6 | Issue 5 | e20375immune responses that explain poor viral control may contribute
more broadly to our understanding of HIV-1 immune pathogen-
esis. In this study, we longitudinally describe the frequency and
phenotype of HIV-specific CD8
+ T cells during primary and
chronic HIV-1 infection in a group of Kenyan infants.
Results
Characteristics of selected participants
The results of IFN-c-ELISPOT assays performed in the
previously characterized cohort study [17] were used to select
infants with high-level responses for more detailed phenotypic
studies using class I HLA tetramers. A total of 85 children became
infected during the course of the study, 72 acquired HIV-1 before
the first month of life, and 61 of these had ELISPOT data. Of
these 61 infants with early HIV-1 acquisition, 26 (43%) had
ELISPOT responses greater than 400 HIVSFU/million PBMC.
Of these, 7 infants had responses directed at HIV-1 epitopes for
which we were able to construct tetramers and had sufficient cells
cryopreserved for flow cytometry studies. Table 1 shows the
virologic and immunologic characteristics for the selected infants.
The median peak response to these peptides was 993 HIVSFU/
10
6 PBMC (Table 1, range 450–2040). HIV-1 RNA viral loads
were high, the mean peak was 6.7 log10 (SD 60.65) and the mean
set-point was 6.2 log10 copies/ml (SD 60.53). The level of viral
replication in these seven infants was representative of the overall
cohort from which the children were selected (mean peak and set-
point viral loads of whole infected cohort 6.8, SD 60.74, p=0.7;
6.2 log10 SD 60.66 copies/ml, p=1.0). At 6 months of age, the
selected infants’ median CD4 percentage was 26% (IQR=21–
29%); similar to that of the overall infected cohort (21%, IQR
=12–28%, p=0.2). Six of the 7 infants had CD4 percentages
meeting WHO criteria [24] for advanced (3 infants) or severe (3
infants) immunosuppression and two did not survive the 2-year
follow-up period. The HLA-A29 allele, which was associated with
a trend for increased risk of early HIV-1 acquisition in the overall
cohort [25], was present in 4 of the children studied here. HLA-
A29 is common in Kenya and 13% (8/61) of children with early
HIV-1 infection in the cohort had this allele. The A29-GP120
epitope was among the most immunodominant epitopes targeted
in the cohort; 5 of 8 (63%) HLA-A29
+ children had positive
ELISPOT responses to A29-GP120 during the first year of life
[17].
Frequencies of HIV-specific CD8
+ T cells
Seven infants provided a median of 4 cryopreserved specimens
(range 1–7 specimens) for tetramer staining. Tetramer staining
detected HIV-specific CD8
+ T cells in all 7 infants. Figure 1A
shows an example of tetramer staining in subject B1-093 who was
diagnosed with HIV-1 infection at birth. Though this infant had
acquired HIV-1 in utero, no responses to the HLA-A29 GP120
epitope were detected by ELISPOT until 3 months of age, at
which time 3.9% of CD3
+CD8
+ T cells were tetramer-positive.
There was a decline in cells detected by tetramer in infant B1-093
after 3 months of age, though a discrete population of A29-GP120
specific cells remained discernable at 24 months. The median peak
frequency of tetramer staining in the group of infants was 1.5% of
CD3
+CD8
+ cells (range 0.088–3.9%) and declined thereafter
(Figure 1C).
Figure 1D shows tetramer staining, ELISPOT, and HIV-1 viral
load data for each infant. In order to compare HIV-specific CD8
T cells identified by tetramer and ELISPOT, we show the number
of tetramer-positive cells/10
6 PBMC. Tetramer staining consis-
tently detected more HIV-epitope-specific CD8
+ T cells than
ELISPOT, in agreement with previous reports that only a subset
of HIV-specific CD8
+ T cells secrete IFN-c [26,27]. Although
substantial numbers of tetramer-positive and IFN-c-secreting
HIV-specific CD8
+ T cells were detected during infant HIV-1
infection, we observed minimal decline in HIV-1 viral loads
during study follow-up; viral loads remained above 5 log10 copies/
ml in all 7 infants and did not appear to follow a pattern similar to
either tetramer-positive or IFN-c-secreting cell frequencies.
Phenotypic characterization of infant HIV-specific CD8
+ T
cells
Analysis of the overall CD8
+ and HIV-specific CD8
+ T cell
subsets demonstrated a phenotype similar to that observed in
adults undergoing acute HIV-1 infection. Figure 2 shows
longitudinal CD8
+ T cell phenotype of a representative infant
Table 1. Infant characteristics.
Infant
HIV
infection
Log HIV
peak
Log HIV
set-point
Month 6
CD4%
Months
Follow-up Class I HLA type
HLA restriction and
immunodominant
epitope
Maximum IFN-c-
ELISPOT response in
year 1 (per 10
6 PBMC)
B1-045 in utero 6.3 5.2 35 24 A1, A3, B15, B57, Cw4, Cw7 A*03 Nef-
QVPLRPMTYK
1170 HIVSFU
B1-093 in utero 6.7 6.4 21 24 A29, A74, B14, B1503, Cw2 A*29 GP120-
FNCGGEFFY
993 HIVSFU
B1-159 peripartum 6.9 5.8 26 24 A29, A30, B4501, Cw6 A*29 GP120-
FNCGGEFFY
723 HIVSFU
B1-170 in utero 5.9 5.2 21 18
b A30, A3402, B42, B57, Cw7,
Cw17
B*57 P24-
KAFSPEVIPMF
1433 HIVSFU
B1-291 peripartum 7.2 6.8 14 15
b A29, A74, B42, B15, Cw2,
Cw17
A*29 GP120-
FNCGGEFFY
685 HIVSFU
B1-334 peripartum 6.5 6.2 26 9
b A29, A26, B13, B15, Cw2,
Cw6
A*29 GP120-
FNCGGEFFY
2040 HIVSFU
B1-454 peripartum 7.6 7.1 29 24 A2, A31, B8, B15, Cw7, Cw8 B*08 Nef-
FLKEKGGL
450 HIVSFU
aB1-045 did not have CD4 data at 6 months, data from 9 months are shown.
bB1-170 was declared lost to follow-up, B1-291 and 334 died at 17 and 11 months of age, respectively.
doi:10.1371/journal.pone.0020375.t001
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+ T cell subset
wasa homogenousmixture ofCD27
+CD28
+(early),CD27
+CD28
2
(intermediate) and CD27
2CD28
2 (late) differentiated cells, HIV-
specific CD8
+ T cells were predominantly CD27
+CD28
2
(Figure 2A). A subset of CD3
+CD8
+ expressed both CD45RA
and CD57, suggesting the generation of terminally differentiated
effector cells (Figure 2B). Consistent with their role as effector cells,
CD45RA
+CD57
+ cells expressedhighlevels of HLA-DR, indicative
of activation (data not shown). Both the overall CD8
+ and HIV-
specific CD8
+ T cell subsets contained high frequencies of HLA-
DR
+ (Figure 2C) and CD95
+ cells (Figure 2D).
Longitudinal changes in T cell phenotype during infant
HIV-1 infection
Figure 3 shows longitudinal data from early through chronic
infection in the overall CD8
+ and HIV-specific CD8
+ T cell
subsets. Since the study specimens were collected at a variety of
time-points, we created time intervals of 3–6 months, 7–12 months
and 23–24 months post HIV-1 infection to enable quantitative
comparisons of overall CD8
+ and HIV-specific CD8
+ T cell
subsets and the description of changes over time (Table 2). HIV-
specific CD8
+ T cells were highly polarized toward an interme-
diate, activated phenotype compared to the overall CD8
+ T cell
       
 
 
       
   
   
 
Figure 1. Tetramer-staining reveals the expansion of HIV-1 specific CD8 T cells during acute infant HIV-1 infection. A) Representative
HLA-A29 GP120 tetramer staining from B1-093, who acquired HIV-1 in utero. Plots show cells gated on CD3+ lymphocytes. Frequencies of tetramer-
positive cells are provided as a percent of CD3
+CD8
+ gated cells. B) Tetramer staining from a negative control donor. C) Frequency of tetramer-
positive cells, expressed as a percentage of the CD3
+CD8
+ subset. Colored lines and markers show individual infants, bold dashed line shows a
median spline. D) HIV-1 RNA viral load (solid line with squares, left y-axis), ELISPOT HIVSFU/million PBMC (dashed line with circles, right y-axis), and
Tetramer+/10
6 PBMC (HIV-specific CD8+ T cells, dotted line with triangles, right y-axis) are shown for each of the 7 infants. Note, ELISPOT assays were
conducted during live cohort follow-up for 1 year, viral load was measured at each study visit over 2 years of follow-up, tetramer staining was
performed on all available frozen specimens. Missing values at visits indicate missed visit or specimen not available for assay.
doi:10.1371/journal.pone.0020375.g001
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+CD28
2 cells was higher in the
HIV-specific CD8
+ T cell subset (mean 73%, range 41–83)
compared to the overall CD8
+ T cell subset (27%, range 7.0–48)
during the 7–12 month interval (p=0.018). HLA-DR
+ cells were
detected at high levels in the HIV-specific CD8
+ T cell subset
compared to the overall CD8
+ subset at 3–6 months (81%, range
45–97 versus 43%, range 35–62, respectively; p=0.017), 7–12
months (79%, range 45–90 versus 39% range 24–51, respectively;
p=0.005), and 23–24 months post HIV-1 infection (80%, range
68–85 versus 34%, range 32–35%, respectively; p=0.0032).
Similarly, CD95
+ cells were detected at a higher frequency in
the HIV-specific CD8
+ T cell subset compared to the overall
CD8
+ subset at 3–6 months (92%, range 28–95 versus 56%, range
8.4–78, respectively; p=0.027), 7–12 months (83%, range 46–91
versus 47%, range 16–63, respectively; p=0.010), and 23–24
months (88%, range 79–96 versus 47%, range 34–61, respectively;
p=0.030) post HIV-1 infection.
Despite the small sample size and limited power, some
longitudinal trends were observed. Notably, the frequency of
CD27+CD28- cells predominated the HIV-specific CD8
+ T cell
subset throughout infection, and very few cells transitioned to lose
CD27 expression by 23–24 months (mean 3.9%, range 1.1–6.1%).
The proportion of cells expressing CD57 increased over time in
the overall CD8
+ T cell subset from 33% (range 15–85) at 3–6
months to 60% (range 53–71) at 23–24 months in the HIV-specific
CD8
+ T cell subset (p=0.20). HLA-DR and CD95 expression
remained high in both the overall CD8
+ and HIV-specific CD8
+ T
cell subsets throughout infection.
In summary, both the overall and HIV-specific CD8
+ T cell
subsets underwent changes during early and chronic infection; the
HIV-specific CD8
+ T cell subset was remarkable in the high
frequency of cells maintaining activation and pro-apoptotic
markers during chronic infection.
Discussion
In this study we determined the longitudinal frequency and
phenotype of HIV-specific CD8
+ T cells during primary and
chronic infant HIV-1 infection. Infants were able to generate
HIV-specific CD8
+ T cells similar to adults in frequency and
Figure 2. Differentiation of infant CD8 T cells during early and chronic infant HIV-1 infection. Dot plots and histograms show
representative phenotyping during the first two years of life in subject B1-093, who was HIV-1 RNA positive at birth. Dot plots show A) CD27 and
CD28 and B) CD45RA and CD57 staining. HIV-specific CD8
+ T cells (gated on tetramer
+/CD3
+CD8
+) are shown as black dot plots overlaid on the overall
CD8
+ subset (gated on CD3
+CD8
+), which are shown as density plots in gray. Quadrant statistics are shown below each dot plot, for the overall CD8
+
(left diagram) and HIV-specific CD8
+ T cell subsets (right diagram). Histograms show C) HLA-DR and D) CD95 staining, the overall CD8
+ subset is
shown by the solid gray histogram, and the HIV-specific CD8
+ T cell subset is overlaid in black outline as an unshaded histogram. Histogram gate
percentages are shown above the plots for the overall CD8
+, and HIV-specific CD8
+ T cell subsets, respectively.
doi:10.1371/journal.pone.0020375.g002
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infection, HIV-specific CD8
+ T cells maintained an activated
phenotype and expressed CD95, suggesting vulnerability to
apoptosis. Persistent activation and expression of CD95 on HIV-
specific CD8
+ T cells may result in the apoptotic elimination of
virus-specific T cells, further enabling the persistence of viral
replication, and perhaps explaining the poor prognosis of HIV-1
infected infants. Alternatively, infant T cells may be compromised
in their transition to a resting phenotype during early infection,
and this in turn could facilitate viral replication.
During early HIV-1 infection in infants, we detected HIV-
specific CD8
+ T cells binding a single tetramer at frequencies as
high as 3.9%, which is similar to those observed in adults (0.1–3%)
[13,28,29,30], and older children (0.1–2.4%) [19,20,31]. Though
high frequencies of tetramer-positive cells were detected during
infant HIV-1 infection, this did not confer a measurable advantage
in the control of viral replication; infants maintained very high
viral loads during the period of observation and two died during
the study. Adult studies of acute HIV-1 infection have shown
decreases in the frequency of tetramer-positive cells following the
initiation of ART [30,32]. In a single study of adults not on ART,
tetramer-positive cells declined following acute infection, presum-
ably due to effective host immune responses and concomitant
reduction of HIV-1 load [33]. During chronic infection in adults,
the frequency of tetramer-staining cells typically follows a pattern
which closely follows changes in viral load [13]. In the 3 infants
followed until 2 years of age, we observed a decline in tetramer-
staining cells despite persistently high HIV-1 viral loads, suggesting
high levels of antigen do not sustain continued HIV-specific CD8
+
expansion.
The differentiation phenotype of infant HIV-specific CD8
+ T
cells was similar to adults; HIV-specific CD8
+ T cells were
primarily CD27
+CD28
-; a subset of infant CD8
+ T cells expressed
both CD45RA and CD57 and were activated, suggesting terminal
differentiation to an effector phenotype (limited in proliferative
potential but likely cytotoxic [34,35]). This similarity in phenotype
between infants and adults suggests that engagement of the infant
T cell receptor results in propagation of a signal sufficient to drive
cell division and differentiation to a similar stage as is reached in
adults. It is also critical to note that although many of the changes
we observed in the overall CD8
+ T cell subset were likely due to
the outgrowth of HIV-specific cells, the differentiation in the
overall CD8
+ T cell subset may also be influenced by co-infection
with other viruses, particularly cytomegalovirus (CMV), which is
known to drive the expansion of CD8
+ cells with a
CD27
2CD28
2, and CD57
+ phenotype [36,37]. Six of the seven
children in our study had acquired CMV by 3 months of age (data
not shown), suggesting that CMV infection may play an important
role in shaping the characteristics of the infant overall CD8
+ T cell
subset.
In adults, the resolution of acute HIV-1 infection is accompa-
nied by a transition of HIV-specific CD8
+ T cells from a
predominantly activated to a predominantly resting population
following the reduction of viral load by therapy or host immune
responses [32,34]. In contrast, during our observation of 3 infants
during the 2-year post infection period, infant HIV-specific CD8
+
T cells remained predominantly activated, expressing high levels
of HLA-DR and CD95. Activated cells are highly susceptible to
activation induced cell death (AICD), and the expression of CD95
on HIV-specific CD8 confers additional susceptibility to Fas-
mediated apoptosis [38]. HIV-infected macrophages and CD4
+ T
cells upregulate Fas-ligand (CD95L) expression on the cell surface,
enabling them to initiate apoptosis in HIV-specific CTL
expressing CD95 [39,40]. Continuing activation and apoptosis
Figure 3. Changes in the overall and HIV-specific CD8
+ T cell
subsets during the first two years of infection. The frequency of
HIV-specific CD8
+ T cells and overall CD8
+ T cells expressing each
marker or combination of markers are shown for the first two years of
life. All infants were infected by 1 month of age. Connected gray lines
show individual infants with more than 1 measurement of phenotype
(N=5), one infant had only one time point analyzed for phenotype (B1-
334, + symbol).
doi:10.1371/journal.pone.0020375.g003
Infant HIV-Specific T Cells
PLoS ONE | www.plosone.org 5 May 2011 | Volume 6 | Issue 5 | e20375may explain in part the reduction in the frequency of tetramer-
staining cells over time. The persistent activation observed in
infants may be a consequence of a failure to control HIV-1
replication during acute infection, but may also subsequently
impair the immune response against HIV-1 during chronic
infection. In addition to the direct effects of cellular activation
on the survival and removal of HIV-specific cells, persistent
cellular activation also has a more generalized negative effect on
the host; cellular activation is a strong independent predictor of
HIV-1 disease progression, and is likely to contribute significantly
to the depletion of CD4
+ T cells via yet undefined mechanisms
[41,42].
This study has several strengths and also some important
weaknesses to note. Study strengths include the longitudinal
assessment of individuals and the absence of confounding by
antiretroviral therapy. By using cryopreserved specimens, we were
able to batch all of each infant’s specimens in a single experiment;
greatly reducing intra-subject experimental error. A limitation of
the study was that few infants in the larger cohort had ELISPOT
responses of a magnitude and specificity to examine with available
tetramers. These phenotypic data may therefore not be represen-
tative of HIV-specific CD8
+ T cells directed at less dominant
epitopes, or T cells from infants with low level responses.
Additionally, the number of cellular antigens we were able to
examine in the phenotypic studies were restricted by limited cell
numbers in the cryopreserved specimens. Finally, the small sample
size of this study limits our ability to perform meaningful statistical
comparisons of the data; though some phenotypic markers differed
between subsets and time intervals, adjustment for multiple
comparisons retained no significant values.
In summary, our data suggest a model of infant infection in
which high frequencies of phenotypically normal CD8
+ T cells fail
to contain viral replication during acute infection, resulting in
persistent T cell activation during chronic infection. Identifying
the mechanisms underlying age-related differential function of T
cells will be valuable to the design of an HIV-1 vaccine
Table 2. Comparison of overall CD8 and HIV-specific phenotype over the first 2 years of HIV-1 infection.
% (range) cells with phenotype in each time interval
3–6 months 7–12 months 23–24 months p
*
Number of infants 5 5 3
CD27
+CD28
+ (early)
Overall CD8 34 (20–70) 33 (14–71) 46 (30–48) 0.49
HIV-specific 35 (22–39) 17 (7.7–28) 31 (22–32) 0.036
p
** 0.53 0.25 0.012
CD27
+CD28
2 (intermediate)
Overall CD8 23 (12–62) 27 (7.0–48) 35 (34–53) 0.90
HIV-specific 54 (31–71) 73 (41–83) 66 (65–71) 0.23
p
** 0.059 0.018 0.076
CD27-CD28
2 (late)
Overall CD8 5.9 (0.38–62) 19 (1.9–73) 17 (1.4–35) 0.41
HIV-specific 9.1 (0–22) 9.6 (0.29–47) 3.9 (1.1–6.1) 0.75
p
** 0.64 0.076 0.13
CD57
+
Overall CD8 34 (8.8–58) 45 (12–70) 36 (28–61) 0.26
HIV-specific 33 (15–85) 39 (20–73) 60 (53–71) 0.20
p
** 0.32 0.92 0.20
CD45RA
+CD57
+
Overall CD8 14 (2.5–33) 15 (2.4–31) 32 (4.0–35) 0.31
HIV-specific 8.0 (3.0–57) 16 (6.7–42) 32 (12–70) 0.21
p
** 0.31 0.52 0.21
HLA-DR
+
Overall CD8 43 (35–62) 39 (24–51) 34 (32–35) 0.15
HIV-specific 81 (45–97) 79 (45–90) 80 (68–85) 0.017
p
** 0.017 0.0050 0.0032
CD95
+
Overall CD8 56 (8.4–78) 47 (16–63) 47 (34–61) 0.33
HIV-specific 92 (28–95) 83 (46–91) 88 (79–96) 0.42
p
** 0.027 0.010 0.030
Notes. Five infants have paired data at 3–6 and 7–12 month intervals, 3 infants have data at all 3 intervals.
*p value for comparison of 3–6 versus 23–24 month interval data.
**p value for comparison of overall CD8 versus HIV-specific (tetramer) data at each interval. No p values met significance following Holm Test for multiple comparisons.
doi:10.1371/journal.pone.0020375.t002
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HIV-specific immunity.
Materials and Methods
Participants and cohort study design
The study was approved by the Ethics and Research Committee
of Kenyatta National Hospital and the Institutional Review Board
of the University of Washington. Mothers provided written
informed consent for study participation on behalf of themselves
and their infants. Details of the cohort recruitment and follow-up
have been presented in detail elsewhere [9,17,43]. The cohort was
enrolled and followed-up before antiretroviral therapy (ART)
became widely available in Kenya; other than maternal antenatal
zidovudine prophylaxis [44], infants did not receive ART. Serial
blood specimens were obtained at delivery and months 1 and 3,
and quarterly thereafter. Children were followed until death or
exit from the study at two years of age. A subset of 7 infants was
selected from this well-characterized cohort for immunologic
studies based on timing of HIV-1 acquisition, previously
characterized immune responses and availability of frozen
specimens.
HIV-1 diagnosis and viral loads
HIV-1 RNA viral loads were measured using the Gen-Probe
transcription mediated assay [45]. Infant HIV-1 infection was
diagnosed by nested PCR amplifying HIV-1 Gag proviral DNA
from dried blood spotted onto filter paper [46]. Infant HIV-1
infection in utero was defined as the detection of either HIV-1 DNA
or RNA within 48 hours of birth, followed by a positive specimen
(viral RNA or DNA) at the subsequent clinic visit. Consistent with
our other studies, the peak HIV-1 viral load was defined as the
highest measurement obtained during the first 6 months of
infection, and the set-point viral load was defined as the first viral
load measured at least 6 weeks after the peak [47].
IFN-c ELISPOT Assay
Amplification refractory mutation system-PCR was used to
determine infant HLA types [48]. Peptides were selected on the
basis of HLA type from a panel of optimized HIV-1 subtype A and
D CD8
+ T cell epitopes previously identified in studies of Kenyan
sex workers [17,49]. Enzyme-linked immunospot assays (ELI-
SPOT) were performed on freshly isolated PBMC obtained from
EDTA anticoagulated blood as previously described [17,50]. Spot
forming units (SFU) was defined as the average number of spots in
duplicate peptide test wells, and HIV-1-specific SFU (HIVSFU)
was defined as SFU minus the average number of spots in the
duplicate negative control wells.
Class I HLA-tetramers and antibody and tetramer staining
The following tetramers were produced in our laboratory as
previously described [28]: HLA-A03-Nef-QVPLRPMTYK, B08-
Nef-FLKEKGGL, and B57-P24-KAFSPEVIPMF, A29-GP120-
FNCGGEFFY. All tetramers were produced using extravidin-PE
(Sigma, Gillingham, UK) as the fluorochrome label. HIV-1
infected infants who had acquired HIV-1 by 1 month of age,
and had ELISPOT responses .400 HIVSFU/10
6 PBMC in fresh
assays were selected for tetramer staining. This threshold was
chosen because tetramer staining is often unable to confirm
ELISPOT responses below this level. All serial specimens from
each individual infant were stained and analyzed on the same day
to minimize intra-patient variation. Cryopreserved specimens
were thawed in fetal calf serum (FCS) and stained with tetramer.
Cells were stained with tetramer-PE, CD3-Pacific Blue (clone
UCHT1, Dako Cytomation, Angel Drove, UK), CD8-APC-Cy7
(clone RPA-T8, Pharmingen), CD38-PE-Cy5 (clone HIT2,
Pharmingen, Oxford, UK), CD28-FITC (clone CD28.1, Dako
Cytomation), CD27-APC (clone 0323, eBioscience, San Diego,
CA, USA), HLA-DR-PE-Cy5 (clone G45-6, Pharmingen), CD57-
FITC (clone TB01, Serotec, Kidlington, UK) and CD45RA-APC
(clone HI100, Pharmingen), and CD95-APC (clone DX2,
Pharmingen). No phenotyping was available for infant B1-454,
whose cells were stained with CD3, CD8 and tetramer only. Cells
were acquired on a Cyan instrument using Summit software (Dako
Cytomation) and analyzed with FlowJo software (Treestar, Inc.,
Olten Switzerland). HIV-1 negative donor cells from an HIV-
uninfected adult were used to confirm an absence of staining for
each tetramer. Gates for fluorochrome-conjugated antibodies were
placed with the aid of isotype controls. Tetramer
+ cells/million
PBMC was calculated by dividing the number of events in the
tetramer gate by the number of events acquired, excluding the
cluster of FSC
verylow/SSC
verylow events likely to be debris or
necrotic cells. Further details of compensations, isotype controls,
and gating schema can be found in File S1 accompanying this
article.
Statistical Analysis
Clinical and laboratory data were collected and stored in a
Microsoft Access Database (Microsoft Inc., Redmond, Washing-
ton, USA) and analyzed using Stata SE v.11 for Macintosh (Stata
Corp. College Station, Texas, USA). Viral loads were log10-
tranformed before comparisons of means using the t-test. Median
CD4 values were compared using the Mann Whitney U test.
Comparisons of cellular phenotype between time intervals, and
between the HIV-specific and overall CD8
+ T cell subsets were
performed using the paired t-test on log10-transformed data; one
infant had .1 measurement within an interval, measurements
were averaged for this individual. We used the Holm Test to
evaluate p values with non-independent multiple comparisons
[51]. All reported p values are two tailed.
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